搜尋

file (3)

What We Do

學術發表

首頁學術發表

2021.Jul.15

Prodrug

A novel selective AKR1C3-activated prodrug AST-3424/OBI-3424 exhibits broad anti-tumor activity

2021.Jun.01

ADC

Preclinical Studies of OBI-999: A Novel Globo H–Targeting Antibody–Drug Conjugate

2021.Apr.10

Vaccine

Inhibitory activity of Globo-H and SSEA-4 on activated T cells

Poster

2021.Apr.10

Prodrug

Selective and Broad Anti-tumor Activity of AKR1C3-activated Prodrug AST-3424/OBI-3424

Poster

2021.Apr.10

ADC

Preclinical characterization of a novel SSEA4-targeting antibody drug conjugate, OBI-998

Poster

2020.Nov.19

Vaccine

A phase I cohort expansion trial of OBI-833 in non-small cell lung cancer patients

Poster

2020.Nov.19

Vaccine

OBI-833 was safe and immunogenic, without treatment-related SAEs, in a phase I dose-escalation trial

Presentation Slides

2020.Jul.22

Vaccine

Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study

2020.May.29

Prodrug

A First-In-Man Phase 1/2 Study of OBI-3424, an AKR1C3-Selective Bis-Alkylating Agent Prodrug, in Subjects With Advanced Cancer, Including Hepatocellular Carcinoma (HCC) and Castrate-Resistant Prostate Cancer (CRPC)

Poster

2020.May.29

Vaccine

The GLORIA Study: A Phase 3, Randomized, Open-Label Study of the Anti-Globo H Vaccine Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients with High Risk, Early-Stage, Globo H-Positive, Triple Negative Breast Cancer

Poster